Superpower Real Customer Outcomes: An Independent Review of Lab, GLP-1, and Peptide Services

What Superpower Actually Offers

Superpower positions itself as a one-stop concierge for people who want lab work, prescriptions, and ongoing optimization under a single subscription. The platform bundles diagnostic testing with access to GLP-1 receptor agonists like semaglutide and tirzepatide, various peptide therapies, and hormone protocols.

The Subscription Concierge Model

The concierge model means you pay a recurring fee for platform access, then pay separately for labs, medications, and consultations. This differs from traditional telehealth platforms where you pay per visit. The bundled approach can simplify logistics, but it also means you are paying for access whether or not you use every service each month.

Lab Testing and Diagnostics

Superpower offers panels that typically include comprehensive metabolic profiles, thyroid function, sex hormones, inflammatory markers like hsCRP, and sometimes advanced lipid panels. These are standard CLIA-certified lab tests available through most telehealth platforms and direct-to-consumer services. The value proposition is not the labs themselves but the interpretation layer and prescribing pathway built on top of the results.

What Gets Prescribed

The medication menu spans GLP-1 receptor agonists for weight management, peptides like BPC-157 and CJC-1295/Ipamorelin for recovery and growth hormone secretion, and testosterone or thyroid protocols. Each of these categories carries different levels of regulatory approval and clinical evidence, a distinction Superpower's marketing does not always make clear.

The Evidence Behind GLP-1 Prescriptions From Concierge Platforms

GLP-1 receptor agonists are the strongest clinical asset in Superpower's catalog. The drugs themselves have extensive trial data. The question is whether a concierge platform delivers them as effectively as a structured clinical program.

Semaglutide Trial Data

In the STEP-1 trial (N=1,961), participants receiving semaglutide 2.4 mg weekly lost a mean of 14.9% body weight at 68 weeks compared to 2.4% with placebo [1]. The STEP-5 extension (N=304) demonstrated that weight loss was maintained at 104 weeks with continued use, with participants losing 15.2% of body weight [2]. These results came from structured programs with regular follow-up, dietary counseling, and dose titration protocols.

Tirzepatide Outcomes

The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg produced 22.5% mean weight loss at 72 weeks [3]. A 2023 analysis published in JAMA Internal Medicine found that real-world semaglutide outcomes were roughly 5-7% lower than trial results, partly because of inconsistent follow-up and premature discontinuation [4].

The Platform Gap

That real-world gap matters. Concierge platforms like Superpower must provide structured titration, regular check-ins, and clear discontinuation protocols to approach trial-level outcomes. Dr. Robert Kushner, a professor of medicine at Northwestern University Feinberg School of Medicine, has stated: "The medication is only as good as the program wrapped around it. Without behavioral support and medical monitoring, patients tend to plateau earlier and regain weight faster after stopping." Whether Superpower's concierge model provides that level of structure is something prospective customers should verify before subscribing.

Peptide Therapies: What the Science Supports (and What It Does Not)

Peptides represent the most speculative part of Superpower's offering. The regulatory and evidentiary field here is fundamentally different from GLP-1s.

BPC-157

BPC-157 (Body Protection Compound-157) has shown tissue-healing properties in rodent models, including accelerated tendon, ligament, and gut mucosal repair [5]. No completed, peer-reviewed human randomized controlled trials exist for BPC-157 as of May 2026. The FDA has not approved BPC-157 for any indication, and in 2023, the agency issued warning letters to compounding pharmacies marketing it with unsubstantiated therapeutic claims [6].

Growth Hormone Secretagogues

CJC-1295 and Ipamorelin are growth hormone secretagogues sometimes offered through concierge platforms. A small study (N=21) showed CJC-1295 increased mean GH levels by 2- to 10-fold for up to 6 days after a single dose [7]. Long-term safety and efficacy data in the populations Superpower targets (generally healthy adults seeking optimization) are absent.

The Regulatory Reality

The FDA categorizes most peptides sold through telehealth concierge services as unapproved drugs. In October 2023, the agency added several peptides, including BPC-157, to its list of substances that cannot legally be compounded under Section 503A of the Federal Food, Drug, and Cosmetic Act [6]. Customers should understand that "prescribed by a licensed provider" does not automatically mean "FDA-approved for this use."

Evaluating Customer Outcomes Without Platform-Published Data

Superpower has not published aggregated outcome data, cohort analyses, or patient satisfaction metrics in any peer-reviewed or independently audited format. This is not unusual for telehealth startups, but it limits what can be objectively assessed.

What Online Reviews Suggest

Customer reviews across Reddit, Trustpilot, and health forums describe mixed experiences. Positive reports commonly mention convenience, fast lab turnaround, and responsive support staff. Negative reports cite high cumulative costs, difficulty reaching prescribers for dose adjustments, and vague explanations of peptide benefits.

The Outcome Attribution Problem

Even when customers report weight loss or improved energy, attributing those outcomes specifically to the Superpower platform (versus the medications themselves, lifestyle changes, or placebo response) is impossible without controlled data. A 2022 systematic review in the Journal of Medical Internet Research found that telehealth weight management programs produced clinically meaningful weight loss (5% or greater) in 45-65% of participants, but outcomes varied widely based on program intensity and follow-up frequency [8].

Red Flags to Watch For

Any platform claiming specific outcome percentages ("our patients lose an average of X pounds") without linking to published methodology should be treated with skepticism. The FTC has increased enforcement against health platforms making unsubstantiated outcome claims, including a 2024 action against several telehealth companies for deceptive advertising of GLP-1 results [9].

Superpower vs. Alternatives: A Direct Comparison

Several platforms compete in the lab-plus-prescription concierge space. The differences come down to prescriber access, medication sourcing, follow-up protocols, and total cost.

Clinician Quality and Access

Some concierge platforms employ nurse practitioners exclusively, while others include board-certified endocrinologists or obesity medicine specialists. The American Board of Obesity Medicine (ABOM) has certified approximately 7,000 physicians as of 2025 [10]. Whether Superpower's network includes ABOM-certified prescribers is not clearly disclosed on the platform.

Medication Sourcing

Compounded semaglutide and tirzepatide have been widely available through telehealth platforms during the FDA shortage period. The Endocrine Society released a 2024 statement noting that "compounded GLP-1 receptor agonists lack the bioequivalence testing required of FDA-approved generics, and potency, sterility, and stability may vary between compounding pharmacies" [11]. Customers should ask whether Superpower sources from 503A or 503B pharmacies and whether those pharmacies hold current FDA or state board inspection records.

Cost Transparency

GLP-1 prescriptions through concierge platforms typically range from $300 to $600 per month for compounded versions, with brand-name semaglutide (Wegovy) or tirzepatide (Zepbound) costing $1,000 or more without insurance. Superpower's subscription fee adds to that base medication cost. A direct comparison requires totaling the subscription, consultation fees, lab costs, and medication charges across a 6- to 12-month horizon.

Follow-Up Intensity

The STEP trials included monthly or biweekly check-ins. Platforms that offer quarterly check-ins or on-demand-only follow-up are providing a structurally different intervention. Ask how often Superpower schedules follow-up appointments and whether dose titration is managed proactively or only when the patient requests it.

Hormone Therapy Through Concierge Platforms: What to Verify

Superpower also offers testosterone replacement therapy (TRT) and thyroid optimization protocols. Both are legitimate medical treatments with specific diagnostic criteria.

Testosterone Replacement

The Endocrine Society's 2018 clinical practice guideline recommends TRT only for men with consistently low morning testosterone (below 300 ng/dL on two separate measurements) combined with clinical symptoms [12]. Platforms that prescribe testosterone based on a single lab draw or levels in the low-normal range (300-400 ng/dL) are operating outside guideline recommendations.

Thyroid Protocols

Thyroid optimization through concierge platforms sometimes involves prescribing liothyronine (T3) or desiccated thyroid extract to patients with normal TSH levels. The American Thyroid Association's 2014 guidelines state that "there is insufficient evidence to recommend combination T4/T3 therapy over T4 monotherapy for hypothyroidism" and that treatment of subclinical hypothyroidism (TSH 4.5-10 mIU/L) should be individualized [13].

The Optimization Trap

"Optimization" is a marketing term, not a clinical endpoint. Bringing a testosterone level from 350 to 700 ng/dL may sound appealing, but the TRAVERSE trial (N=5,246) found that testosterone treatment in men aged 45-80 with hypogonadism and cardiovascular risk did not increase major adverse cardiac events but also did not improve cardiovascular outcomes [14]. Benefits were limited to sexual function and, modestly, to bone density. Customers should have realistic expectations about what hormone adjustments will and will not change.

Is Superpower Legit? A Framework for Assessment

Legitimacy in the concierge telehealth space exists on a spectrum. Superpower is a legally operating business with licensed prescribers. That baseline does not answer whether it provides good value or optimal clinical care.

Questions to Ask Before Subscribing

Prospective customers should request the following information: credentials of the specific clinician assigned to their case, the compounding pharmacy name and licensure status, whether treatment protocols follow published guidelines (Endocrine Society, ABOM, ATA), the frequency of scheduled follow-ups, and what happens to prescriptions if they cancel the subscription.

When a Concierge Model Adds Value

A subscription concierge model genuinely adds value when it reduces friction for patients managing multiple conditions, consolidates fragmented care, and maintains proactive monitoring. For a patient on both semaglutide and TRT who needs quarterly labs and monthly dose reviews, a well-run concierge can outperform cobbling together separate providers.

When It Does Not

The model subtracts value when the subscription fee is essentially a paywall for medications available through cheaper channels, when follow-up is passive rather than proactive, or when marketing outpaces the evidence for offered treatments (particularly peptides).

Safety Monitoring Across Superpower's Medication Categories

Any platform prescribing GLP-1s, peptides, and hormones should have clear monitoring protocols. The absence of serious adverse events in customer reviews does not substitute for systematic safety tracking.

GLP-1 Monitoring Requirements

The FDA label for semaglutide requires monitoring for pancreatitis symptoms, gallbladder events, and thyroid nodules [15]. The STEP trials reported gallbladder-related events in 2.6% of semaglutide patients versus 1.2% on placebo. Gastrointestinal side effects (nausea, vomiting, diarrhea) occurred in 44% of semaglutide patients in STEP-1, most commonly during dose escalation [1].

Hormone Monitoring Standards

TRT requires monitoring of hematocrit (to screen for polycythemia), PSA, and liver function at baseline, 3-6 months, and then annually per Endocrine Society guidelines [12]. Thyroid medication adjustments require TSH rechecks 6-8 weeks after any dose change [13]. Customers should confirm that their Superpower protocol includes these follow-ups.

Peptide Safety Gaps

For unapproved peptides, no standardized monitoring protocols exist because no regulatory body has defined them. This means the monitoring you receive depends entirely on individual prescriber judgment. The quality variance between a cautious prescriber who orders regular metabolic panels and one who simply refills without labs can be significant.

Patients starting any GLP-1 through Superpower or a comparable platform should have baseline lipase, amylase, and a thyroid ultrasound if they have a personal or family history of medullary thyroid carcinoma, per the semaglutide prescribing information [15].